Myeloablative reduced-toxicity IV busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life

The optimal pretransplant regimen for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in patients ≥55 years of age remains to be determined. The myeloablative reduced-toxicity 4-day regimen IV busulfan (Bu) (130 mg/m(2))-IV fludarabine (Flu) (40 mg/m(2)) is associated with low morbidi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Biol Blood Marrow Transplant
Autori principali: Alatrash, Gheath, de Lima, Marcos, Hamerschlak, Nelson, Pelosini, Matteo, Wang, Xuemei, Xiao, Lianchun, Kerbauy, Fabio, Chiattone, Alexandre, Rondon, Gabriela, Qazilbash, Muzaffar H., Giralt, Sergio A., de Padua Silva, Leandro, Hosing, Chitra, Kebriaei, Partow, Zhang, Weiqing, Nieto, Yago, Saliba, Rima M., Champlin, Richard E., Andersson, Borje S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2011
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4261630/
https://ncbi.nlm.nih.gov/pubmed/21338705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2011.02.007
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi